The management of phosphodiesterase-5 (PDE5) inhibitor failure

Current Vascular Pharmacology

Volumn 4, Issue 2, 2006, Pages 89-93

  Lau, David H W ^a,c   Kommu, Sashi ^b   Mumtaz, Faiz H ^a,c   Morgan, Robert J ^a   Thompson, Cecil S ^a   Mikhailidis, Dimitri P ^a,d  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c CHASE FARM HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Corpus cavernosum; Erectile dysfunction; PDE5 inhibitors; Tachyphylaxis

Indexed keywords

ANGIOTENSIN II ANTAGONIST; APOMORPHINE; DOXAZOSIN; ENDOTHELIN 1; KETANSERIN; LOSARTAN; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; RHO KINASE INHIBITOR; SILDENAFIL; TADALAFIL; TAMSULOSIN; VALSARTAN; VARDENAFIL; CGMP BINDING, CGMP SPECIFIC 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING, CGMP-SPECIFIC 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR;

COMORBIDITY; DIABETES MELLITUS; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; ERECTILE DYSFUNCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; NAUSEA; ORTHOSTATIC HYPERTENSION; REVIEW; RISK FACTOR; TACHYPHYLAXIS; ANIMAL; MALE; ORGANIC IMPOTENCE; PHYSIOLOGY; TREATMENT FAILURE;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; HUMANS; IMPOTENCE, VASCULOGENIC; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; TREATMENT FAILURE;

EID: 33646032437     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016106776359871     Document Type: Review

References (68)

1. Shabsigh R. Therapy of ED: PDE-5 Inhibitors. Endocrine 2004; 23: 135-41.
2. Hartmut P. Phosphodiesterase type-5 inhibitors: a critical comparative analysis. Eur J Urol 2004; 2: 56-63.
3. Tomlinson J, Wright D. Impact of erectile dysfunction and its subsequent treatment with sildenafil: qualitative study. BMJ 2004; 328: 1037.
4. Deng CH, Guo HB. Measures for optimizing the efficacy of sildenafil on patients with erectile dysfunction. Zhonghua Nan Ke Xue 2005; 11: 389-391.
5. Klotz T, Mathers M, Klotz R, Sommer F. Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra)? Int J Impot Res 2005; 17: 2-4.
6. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M; Men's Attitudes to Life Events and Sexuality (MALES) Study. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20: 607-17.
7. El-Galley R, Rutland H, Talic R, Keane T, Clark H. Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol 2001; 166: 927-31.
8. DiFabio J, Ji Y, Vasiliou V, Thatcher GR, Bennett BM. Role of mitochondrial aldehyde dehydrogenase in nitrate tolerance. Mol Pharmacol 2003; 64: 1109-16.
9. Sydow K, Daiber A, Oelze M, Chen Z, August M, Wendt M, et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 2004; 113: 482-9.
10. McMahon CG. High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction. Int J Impot Res 2002; 14: 533-538
11. Hatzichristou DG. Current treatment and future perspectives for erectile dysfunction. Int J Impot Res 1998; 10 Suppl 1: S3-13.
12. Garcia-Reboll L, Mulhall JP, Goldstein I. Drugs for the treatment of impotence. Drugs Aging 1997; 11: 140-51.
13. Derouet H, Osterhage J, Sittinger H. Erectile dysfunction. Epidemiology, physiology, aetiology, diagnosis and therapy. Urologe 2004; 43: 197-207.
14. Briganti A, Salonia A, Gallina A, Suardi N, Rigatti P, Montorsi F. Emerging oral drugs for erectile dysfunction. Expert Opin Emerg Drugs 2004; 9: 179-189.
15. Montorsi F, Salonia A, Deho' F, Cestari A, Guazzoni G, Rigatti P, et al. Pharmacological management of erectile dysfunction. BJU Int 2003; 91: 446-54.
16. Khan MA, Raistrick M, Mikhailidis DP, Morgan RJ. MUSE: clinical experience. Curr Med Res Opin 2002; 18: 64-7.
17. Marmar JL. Vacuum constriction devices. Hellstrom WJG Ed, Male Infertility And Sexual Dysfunction. Springer Verlag, New York 1997; 409.
18. Sidi AA, Becher EF, Zhang G, Lewis JH. Patient acceptance of and satisfaction with an external negative pressure device for impotence. J Urol 1990; 144: 1154-6.
19. Baltaci S, Aydos K, Kosar A, Anafarta K. Treating erectile dysfunction with a vacuum tumescence device: a retrospective analysis of acceptance and satisfaction. Br J Urol 1995; 76: 757-60.
20. Sperling H, Lummen G, Schneider T, Rubben H. New treatment options for erectile dysfunction: pharmacologic and nonpharmacologic options. Herz 2003; 28: 314-24.
21. Milbank AJ, Montague DK. Surgical management of erectile dysfunction. Endocrine 2004; 23: 161-5.
22. Anastasiadis AG, Wilson SK, Burchardt M, Shabsigh R. Long-term outcomes of inflatable penile implants: reliability, patient satisfaction and complication management. Curr Opin Urol 2001; 11: 619-23.
23. Rao DS, Donatucci CF. Vasculogenic impotence. Arterial and venous surgery. Urol Clin North Am 2001; 28: 309-19.
24. Cakan M, Yalcinkaya F, Demirel F, Ozgunay T, Altug U. Is dorsal penile vein ligation (DPVL) still a treatment option in venoocclusive dysfunction? Int Urol Nephrol 2003; 35: 529-34.
25. De Rose AF, Giglio M, Traverso P, Lantieri P, Carmignani G. Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. Int J Impot Res 2002; 14: 50-3.
26. Kaplan SA, Reis RB, Kohn IJ, Shabsigh R, Te AE. Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction. Urology 1998; 52: 739-43.
27. Flack JM. The effect of doxazosin on sexual function in patients with benign prostatic hyperplasia, hypertension, or both. Int J Clin Pract 2002; 56: 527-30.
28. Khan MA, Morgan RJ, Mikhailidis DP. The choice of antihypertensive drugs in patients with erectile dysfunction. Curr Med Res Opin 2002; 18: 103-7.
29. Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005; 47: 824-37.
30. De Rose AF, Carmignani G, Corbu C, Giglio M, Traverso P, Naselli A, et al. Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol Int 2002; 68: 95-8.
31. Hernandez FC, Moncada II, Jara RJ, Castano GI, Moralejo GM. [Treatment with Doxazosin in 3347 patients with lower urinary tract symptoms. Impact on sexual function. The impros study]. Actas Urol Esp 2004; 28: 290-7.
32. Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Hoye K. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 2001; 87: 192-200.
33. Kirby RS, O'Leary MP, Carson C. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. BJU Int 2005; 95: 103-9; discussion 109.
34. Doggrell SA. After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother 2004; 5: 1957-64.
35. Mirone V, Imbimbo C, Fabrizio F, Longo N, Palmieri A. Ketanserin plus prostaglandin E1 (PGE-1) as intracavernosal therapy for patients with erectile dysfunction unresponsive to PGE-1 alone. Br J Urol 1996; 77: 736-9.
36. Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003; Suppl 2: 29-34.
37. Chan P, Liu JC, Tong YC, Chen YJ, Wang CC, Tomlinson B, et al. Effects of losartan on the sexual behavior of male rats. Pharmacology 1999; 58: 132-9.
38. Lau DH, Kommu S. Relaxation effects of adrenomedullin in isolated rabbit corpus cavernosum smooth muscle. BJU Int 2004; 94: 446-7.
39. Gokce G, Bagcivan I, Kilicarslan H, Yildirim S, Gultekin YE, Sarioglu Y. Relaxation effects of adrenomedullin in isolated rabbit corpus cavernosum smooth muscle. BJU Int 2004; 93: 859-62.
40. Nishimatsu H, Hirata Y, Hayakawa H, Nagata D, Satonaka H, Suzuki E, et al. Effects of intracavernous administration of adrenomedullin on erectile function in rats. Peptides 2001; 22: 1913-8.
41. Wilkes N, White S, Stein P, Bernie J, Rajasekaran M. Phosphodiesterase-5 inhibition synergizes rho-kinase antagonism and enhances erectile response in male hypertensive rats. Int J Impot Res 2004; 16: 187-94.
42. Dai Y, Chitaley K, Webb RC, Lewis RW, Mills TM. Topical application of a Rho-kinase inhibitor in rats causes penile erection. Int J Impot Res 2004; 16: 294-8.
43. Mills TM, Lewis RW, Wingard CJ, Linder AE, Jin L, Webb RC. Vasoconstriction, RhoA/Rho-kinase and the erectile response. Int J Impot Res 2003; 15 Suppl 5: S20-4.
44. Chitaley K, Webb RC, Mills TM. Rho-kinase as a potential target for the treatment of erectile dysfunction. Drug News Perspect 2001; 14: 601-6.
45. Buyukafsar K, Un I. Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice. Eur J Pharmacol 2003; 472: 235-8.
46. Filippi S, Crescioli C, Vannelli GB, Fazzini A, Natali A, Riffaud JP, et al. Effects of NCX 4050, a new NO donor, in rabbit and human corpus cavernosum. Int J Androl 2003; 26: 101-8.
47. Khan MA, Thompson CS, Sullivan ME, Dashwood MR, Jeremy JY, Morgan RJ, et al. Endothelin and erectile dysfunction: a target for pharmacological intervention? Expert Opin Investig Drugs 1998; 7: 1759-67.
48. Thompson CS, Khan MA, Dashwood MR, Mumtaz FH, Mikhailidis DP, Morgan RJ. Altered cavernosal endothelin-B-receptor binding sites in the rabbit model of partial bladder outlet obstruction. J Cardiovasc Pharmacol 2000; 36: 260-1.
49. Khan MA, Dashwood MR, Thompson CS, Auld J, Morgan RJ, Mikhailidis DP. Down-regulation of endothelin-B receptor sites in cavernosal tissue of a rabbit model of partial bladder outlet obstruction: potential clinical relevance. World J Urol 1999; 17: 290-5.
50. Sullivan ME, Dashwood MR, Thompson CS, Mikhailidis DP, Morgan RJ. Down-regulation of endothelin-B receptor sites in cavernosal tissue of hypercholesterolaemic rabbits. Br J Urol 1998; 81: 128-34.
51. Sullivan ME, Dashwood MR, Thompson CS, Muddle JR, Mikhailidis DP, Morgan RJ. Alterations in endothelin B receptor sites in cavernosal tissue of diabetic rabbits: potential relevance to the pathogenesis of erectile dysfunction. J Urol 1997; 158: 1966-72.
52. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172: 658-663.
53. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003; 6: 94-99.
54. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003; 58: 632-638.
55. Pomara G, Morelli G, Pomara S, Taddei S, Ghiadoni L, Dinelli N, et al. Cardiovascular parameter changes in patients with erectile dysfunction using PDE-5 inhibitors: a study with sildenafil and vardenafil. J Androl 2004; 25: 625-9.
56. Herschorn S. Cardiovascular safety of PDE5 inhibitors. Can J Urol 2003; 10 Suppl 1: 23-8.
57. Stief CG, Uckert S, Becker AJ, Harringer W, Truss MC, Forssmann WG, et al. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology 2000; 55: 146-50.
58. Kloner RA, Jackson G, Emmick JT, Mitchell MI, Bedding A, Warner MR, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004; 172(5 Pt 1): 1935-40.
59. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004; 171: 2341-5.
60. Shabbir M, Mikhailidis DP, Morgan RJ. Erectile dysfunction: an underdiagnosed condition associated with multiple risk factors. Curr Med Res Opin 2004; 20: 603-6.
61. Moreland RB. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int J Impot Res 1998;10: 113-20.
62. Montorsi F, Briganti A, Salonia A, Rigatti P, Burnett AL. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur Urol 2004; 45: 123-33.
63. Uygur MC, Gur E, Arik AI, Altug U, Erol D. Erectile dysfunction following treatments of benign prostatic hyperplasia: a prospective study. Andrologia 1998; 30: 5-10.
64. Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol 2004; 172: 255-8.
65. Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D'Andrea F, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomised controlled trial. JAMA 2004; 291: 2978-84.
66. Guay AT, Perez JB, Heatley GJ. Cessation of smoking rapidly decreases erectile dysfunction. Endocr Pract 1998; 4: 23-6.
67. Jeremy JY, Mikhailidis DP. Cigarette smoking and erectile dysfunction. J R Soc Health 1998; 118: 151-5.
68. Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000; 56: 302-6.